Dr. Ron Najafi, CEO, to Webcast a Clinical Development Update With Future Milestones for the Company's Four Business Units EMERYVILLE, Calif., March 9, 2011 (GLOBE NEWSWIRE) -- Ron Najafi, PhD, Chairman and Chief Executive Officer of NovaBay Pharmaceuticals (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will be presenting at Roth Capital Partners' 23rd Annual Growth Stock Conference at The Ritz Carlton, Laguna Niguel in Dana Point, California. Dr. Najafi will be speaking in the Healthcare Track (Track 2) on Wednesday, March 16, 2011 at 1:30PM (PDT). Dr. Najafi will discuss the current status of NovaBay's Aganocide ® compounds, which are novel, broad-spectrum, fast-acting antimicrobial molecules designed to mimic the body's defense against infection. When applied topically, these compounds maintain biological activities while demonstrating improved solution stability over naturally occurring antimicrobial molecules. In clinical testing in 129 patients with impetigo infections, the lead Aganocide compounds have been shown to be highly effective against bacteria, including some multi-drug resistant strains such as MRSA with 92% clinical efficacy. In preclinical testing, Aganocide compounds have also shown good activity against viruses and fungi and have the potential to deliver the same or better efficacy than antibiotics. They also address the growing problem of antibiotic resistance by employing a novel mechanism of action. The three-day Roth conference brings together executives from over 400 growth companies, including more than 135 leading biotechnology, pharmaceutical, medical devices/diagnostics and healthcare services companies. The event is designed to provide investors with a unique opportunity to gain insight into small and mid-cap growth companies across a variety of sectors, including energy, software, technology, industrials, healthcare, media, consumer and retail. The conference combines company presentations, Q&A sessions, expert panels and management one-on-one meetings to provide Roth's institutional clients with extensive interaction with senior management to gain in-depth insights into each company.